Warner Chilcott Wins Ruling Blocking Mylan’s Copy of Doryx
Warner Chilcott Plc (WCRX) said it won a court ruling blocking Mylan Inc. from selling a generic version of its Doryx antibiotic.
Warner Chilcott, based in Dublin, sued Mylan in federal court in Newark, New Jersey, in 2009, claiming infringement of various patents, including one issued in 2008 on its 150- milligram tablets.
In granting a preliminary injunction against Mylan, based in Canonsburg, Pennsylvania, U.S. District Judge William Martini ruled that Warner Chilcott had shown a reasonable likelihood of success on its claim that its 150-milligram patent was valid and had been infringed, the Irish drugmaker said today in a statement.
“Mylan believes that the district court erred in its decision to grant plaintiffs’ motion for a preliminary injunction and we intend to seek an expedited trial or other expedited relief from the order,” Mylan spokewoman Nina Devlin said in an e-mail. “Mylan remains confident in its position in the case.”
The ruling couldn’t immediately be confirmed in court records.
The case is Warner Chilcott Laboratories v. Mylan Pharmaceuticals Inc., 09-cv-2073, U.S. District Court, District of New Jersey (Newark).
To contact the reporter on this story: David Voreacos in Newark, New Jersey at firstname.lastname@example.org.
To contact the editor responsible for this story: Michael Hytha at email@example.com.
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.